标题
PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
作者
关键词
-
出版物
Frontiers in Immunology
Volume 13, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-10-20
DOI
10.3389/fimmu.2022.1049043
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The “digital biopsy” in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT
- (2022) Lavinia Monaco et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies
- (2022) Kevin Park et al. Frontiers in Cell and Developmental Biology
- Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
- (2022) Tae Kon Kim et al. NATURE REVIEWS DRUG DISCOVERY
- Association between 18F-FDG metabolic activity and programmed death ligand-1 (PD-L1) expression using 22C3 immunohistochemistry assays in non-small cell lung cancer (NSCLC) resection specimens
- (2021) Long Zhao et al. BRITISH JOURNAL OF RADIOLOGY
- A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab
- (2021) Gil Awada et al. Cancers
- Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
- (2021) Agnese Paderi et al. Cancers
- Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
- (2021) Donghui Wang et al. Frontiers in Oncology
- The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression
- (2021) Karolien Vekens et al. Clinical Lung Cancer
- Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[18F]FDG PET/CT
- (2021) Caixia Wu et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis
- (2021) Yong Fan et al. Frontiers in Oncology
- Correlation Between Dual-Time-Point FDG PET and Tumor Microenvironment Immune Types in Non-Small Cell Lung Cancer
- (2021) Jianyuan Zhou et al. Frontiers in Oncology
- Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study
- (2021) Kenji Morimoto et al. Frontiers in Oncology
- Diagnostic test accuracy of 18F-FDG PET/CT for prediction of programmed death ligand 1 (PD-L1) expression in solid tumours: a meta-analysis
- (2021) H.Y. Seol et al. CLINICAL RADIOLOGY
- Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non–small cell lung cancer treated with first-line pembrolizumab
- (2021) Filippo G. Dall’Olio et al. EUROPEAN JOURNAL OF CANCER
- Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST
- (2021) Kazuhiro Kitajima et al. Japanese Journal of Radiology
- First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer
- (2021) Anna-Larissa Nadia Niemeijer et al. JOURNAL OF NUCLEAR MEDICINE
- Relationship of the standard uptake value of 18F-FDG-PET-CT with tumor-infiltrating lymphocytes in breast tumors measuring ≥ 1 cm
- (2021) Soeun Park et al. Scientific Reports
- Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images
- (2021) Wei Mu et al. Journal for ImmunoTherapy of Cancer
- The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab
- (2021) Matteo Bauckneht et al. Cancers
- FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma
- (2021) F. Dimitriou et al. ANNALS OF ONCOLOGY
- 89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer
- (2021) I.C. Kok et al. ANNALS OF ONCOLOGY
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
- (2021) Golnaz Morad et al. CELL
- Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study
- (2021) Nežka Hribernik et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Tumour burden and efficacy of immune-checkpoint inhibitors
- (2021) Filippo G. Dall’Olio et al. Nature Reviews Clinical Oncology
- Prognostic importance of SUV-max values evaluated by 18F-FDG-PET/CT before nivolumab treatment in patients with metastatic renal cell carcinoma
- (2021) Ilkay GULTURK et al. QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer
- (2021) Jianyuan Zhou et al. Frontiers in Oncology
- Evaluation of PD-L1 Expression Level in Patients With Non-Small Cell Lung Cancer by 18F-FDG PET/CT Radiomics and Clinicopathological Characteristics
- (2021) Jihui Li et al. Frontiers in Oncology
- FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer
- (2020) Tomoko Hirakata et al. BREAST CANCER RESEARCH AND TREATMENT
- Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma
- (2020) Maria Togo et al. BRITISH JOURNAL OF CANCER
- 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer
- (2020) Kyle G. Mitchell et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- ICOS Is an Indicator of T-cell–Mediated Response to Cancer Immunotherapy
- (2020) Zunyu Xiao et al. CANCER RESEARCH
- Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4
- (2020) Romain-David Seban et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- The immunological Warburg effect: Can a metabolic‐tumor‐stroma score (MeTS) guide cancer immunotherapy?
- (2020) Peter J. Siska et al. IMMUNOLOGICAL REVIEWS
- Imaging the cancer immune environment and its response to pharmacological intervention- Part 1- The role of FDG PET/CT
- (2020) Amir Iravani et al. JOURNAL OF NUCLEAR MEDICINE
- 18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma
- (2020) Annie Wong et al. CANCER IMAGING
- Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
- (2020) Eli P. Darnell et al. Current Oncology Reports
- PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer
- (2020) Xiaodong Wu et al. EJNMMI Research
- Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
- (2020) Kosuke Hashimoto et al. Journal of Clinical Medicine
- 18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival
- (2020) Giulia Polverari et al. Cancers
- The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
- (2020) Yuanyuan Zhang et al. Cellular & Molecular Immunology
- Association between the occurrence and spectrum of immune-related adverse events and efficacy of pembrolizumab in Asian patients with advanced urothelial cancer: Multicenter retrospective analyses and systematic literature review
- (2020) Toshiki Kijima et al. Clinical Genitourinary Cancer
- Relationship between SP142 PD-L1 Expression and 18F-FDG Uptake in Non-Small-Cell Lung Cancer
- (2020) Long Zhao et al. Contrast Media & Molecular Imaging
- Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study
- (2020) David Chardin et al. Journal for ImmunoTherapy of Cancer
- Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1
- (2020) Angelo Castello et al. Frontiers in Oncology
- FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer
- (2020) Romain-David Seban et al. ANNALS OF NUCLEAR MEDICINE
- Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET
- (2020) Federico Simonetta et al. CLINICAL CANCER RESEARCH
- Imaging findings of immune checkpoint inhibitor associated pancreatitis
- (2020) Jeeban P. Das et al. EUROPEAN JOURNAL OF RADIOLOGY
- Imaging the cancer immune environment and its response to pharmacological intervention- Part 2- The Role of Novel PET Agents
- (2020) Amir Iravani et al. JOURNAL OF NUCLEAR MEDICINE
- Non-invasive decision support for NSCLC treatment using PET/CT radiomics
- (2020) Wei Mu et al. Nature Communications
- Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
- (2020) Ou Yamaguchi et al. Scientific Reports
- The potential of 18F-FDG PET/CT in predicting PDL1 expression status in pulmonary lesions of untreated stage IIIB-IV non-small-cell lung cancer
- (2020) Lihua Wang et al. LUNG CANCER
- Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer
- (2019) Ruohua Chen et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
- (2019) Lucas Goldfarb et al. EJNMMI Research
- Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT
- (2019) Tomomi Nobashi et al. CLINICAL NUCLEAR MEDICINE
- Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non–Small Cell Lung Cancer
- (2019) Lucian Beer et al. CLINICAL NUCLEAR MEDICINE
- The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer
- (2019) Shinsuke Sasada et al. BREAST CANCER RESEARCH AND TREATMENT
- 18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer
- (2019) Mario Jreige et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics
- (2019) Romain-David Seban et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response
- (2019) Joseph Vento et al. Journal for ImmunoTherapy of Cancer
- New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer
- (2019) Yang Wang et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Immunity, Hypoxia and Metabolism - the ménage à trois of cancer: implications for immunotherapy
- (2019) Carla Riera-Domingo et al. PHYSIOLOGICAL REVIEWS
- Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
- (2019) Romain-David Seban et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- First-in-human imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting
- (2019) Neeta Pandit-Taskar et al. JOURNAL OF NUCLEAR MEDICINE
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy
- (2019) Wei Mu et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Hyper-progressive Disease in Patients With Non–Small Cell Lung Cancer Treated With Checkpoint Inhibitors: The Role of 18F-FDG PET/CT
- (2019) Angelo Castello et al. JOURNAL OF NUCLEAR MEDICINE
- Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy
- (2018) Tina Cascone et al. Cell Metabolism
- The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma
- (2018) Christos Sachpekidis et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
- (2018) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas
- (2018) Tsuyoshi Hamada et al. OncoImmunology
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
- (2018) Jason Zhu et al. Journal for ImmunoTherapy of Cancer
- Interferon-gamma PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy
- (2018) Heather M Gibson et al. CANCER RESEARCH
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Adverse effects and radiological manifestations of new immunotherapy agents
- (2018) Yen Zhi Tang et al. BRITISH JOURNAL OF RADIOLOGY
- Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy
- (2018) Kimiteru Ito et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect
- (2018) Yang Du et al. EUROPEAN RADIOLOGY
- F-18 FDG PET/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma
- (2018) Kimiteru Ito et al. JOURNAL OF NUCLEAR MEDICINE
- 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab
- (2018) Christos Sachpekidis et al. MELANOMA RESEARCH
- 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
- (2018) Frederike Bensch et al. NATURE MEDICINE
- PD-1 Blockade–induced Inflammatory Arthritis
- (2018) Tomomi Nobashi et al. RADIOLOGY
- Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab
- (2017) Hoda Anwar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Oxygen availability and metabolic reprogramming in cancer
- (2017) Hong Xie et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells
- (2017) Mohammad Rashidian et al. JOURNAL OF EXPERIMENTAL MEDICINE
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
- (2017) Robert Brody et al. LUNG CANCER
- ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer
- (2017) Emily B. Ehlerding et al. MOLECULAR PHARMACEUTICS
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Potential Utility of FDG PET-CT as a Non-invasive Tool for Monitoring Local Immune Responses
- (2017) Seungho Lee et al. Journal of Gastric Cancer
- Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery
- (2016) Egesta Lopci et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma
- (2011) Stephanos Pavlides et al. CELL CYCLE
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
- (2009) R. L. Wahl et al. JOURNAL OF NUCLEAR MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now